Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42207 | 0.90 | ACHE (0.67) | DRD2DRD4DRD3ACHECCR3 | |
| Hydrochloric Acid SCHEMBL1624601 | 0.88 | ACHE (0.65) | DRD2DRD4DRD3ACHECCR3 | |
| Hydrochloric Acid SCHEMBL2673764 | 0.88 | ACHE (0.65) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL1204089 | 0.87 | TRPV6 (0.58) | DRD2DRD4DRD3RECQLSMN1; SMN2 | |
| SCHEMBL3709310 | 0.86 | RECQL (0.70) | DRD2DRD4DRD3RECQLSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27529844 | 0.86 | ACHE (0.62) | DRD2DRD4DRD3ACHECCR3 | |
| Methylene Chloride SCHEMBL27437437 | 0.86 | ACHE (0.62) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL13990656 | 0.85 | L3MBTL3 (0.68) | DRD2DRD4DRD3RECQLSMN1; SMN2 | |
| SCHEMBL3285312 | 0.85 | DRD2 (0.65) | DRD2DRD4DRD3RECQLSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3706762 | 0.85 | RECQL (0.68) | DRD2DRD4DRD3RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| WO-2009130016-A1 | DIHYDROPTERIDINONES AS PLK INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112152-A1 | Dihydropteridinones as Plk Inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | DRD2 241/4885DRD4 329/4885DRD3 247/4885 |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | DRD2 241/4885DRD4 329/4885DRD3 247/4885 |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | DRD2 241/4885DRD4 329/4885DRD3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.